Treatment With Remdesivir Plus Dexamethasone Linked To Fewer Deaths Among Patients Hospitalized For COVID-19, Study Finds

MedPage Today (9/24, Kahn) reports, “Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study suggested.” Researchers found that “the drug duo was associated with an overall 26% reduction in mortality at 14 days...and an overall 24% reduction at 28 days...when compared with dexamethasone alone.” The findings were published in Clinical Infectious Diseases.